
- 要闻
- SWS透析护理有限公司(SHSE:688410)在投资者中的受欢迎程度显而易见
SWS Hemodialysis Care Co., Ltd.'s (SHSE:688410) Popularity With Investors Is Clear
SWS Hemodialysis Care Co., Ltd.'s (SHSE:688410) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 52.4x SWS Hemodialysis Care Co., Ltd. (SHSE:688410) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E ratios under 35x and even P/E's lower than 20x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's as high as it is.
Recent times haven't been advantageous for SWS Hemodialysis Care as its earnings have been falling quicker than most other companies. It might be that many expect the dismal earnings performance to recover substantially, which has kept the P/E from collapsing. If not, then existing shareholders may be very nervous about the viability of the share price.

How Is SWS Hemodialysis Care's Growth Trending?
There's an inherent assumption that a company should outperform the market for P/E ratios like SWS Hemodialysis Care's to be considered reasonable.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 64%. Still, the latest three year period has seen an excellent 190% overall rise in EPS, in spite of its unsatisfying short-term performance. Although it's been a bumpy ride, it's still fair to say the earnings growth recently has been more than adequate for the company.
Turning to the outlook, the next year should generate growth of 194% as estimated by the only analyst watching the company. That's shaping up to be materially higher than the 41% growth forecast for the broader market.
With this information, we can see why SWS Hemodialysis Care is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
The Final Word
We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.
We've established that SWS Hemodialysis Care maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. It's hard to see the share price falling strongly in the near future under these circumstances.
It is also worth noting that we have found 3 warning signs for SWS Hemodialysis Care that you need to take into consideration.
If you're unsure about the strength of SWS Hemodialysis Care's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
中国透析护理有限公司(SHSE:688410)的市盈率为52.4倍,目前可能正在发出消极信号,因为中国近一半的公司市盈率低于35倍,甚至低于20倍的市盈率并不罕见。 尽管如此,仅仅根据市盈率情况判断可能不明智,因为导致市盈率高的原因可能会有解释。
近期对于中国透析护理来说并不如意,其盈利下降速度比大多数其他公司要快。许多人可能预计糟糕的盈利表现会得到显著恢复,这导致市盈率没有崩溃。如果没有恢复,那么现有股东可能会非常担心股价的可持续性。

中国透析护理增长趋势如何?
存在一种固有的假设,即公司应当表现优于市场,才能认为像中国透析护理这样的市盈率是合理的。
首先回顾一下,去年公司的每股收益增长并不令人兴奋,因为它录得了令人失望的64%下降。尽管短期表现不佳,但最近三年的总体EPS增长率却达到了出色的190%。虽然曲折,但仍然可以说,最近的盈利增长对公司来说已经足够了。
转向展望,根据唯一分析师对公司的估计,明年预计将实现194%的增长。这个增长预期明显高于更广泛市场的41%增长预测。
根据这一信息,我们可以看到,SWS透析护理的股价相比市场较高PE,原因在于股东们似乎不急于抛售,因为这家公司有可能迎来更为繁荣的未来。
最终结论
我们会说市盈率的力量不是作为估值工具,而是用于衡量当前投资者的情绪和未来预期。
我们已经确定,SWS透析护理保持了较高的PE,因为其预期增长高于更广泛市场,这是意料之中的。目前股东对PE感到满意,因为他们相当有信心未来的盈利不会受到威胁。在这些情况下,很难看到股价在不久的将来大幅下跌。
值得注意的是,我们发现了3个SWS透析保健的警告信号,您需要考虑。
如果您对SWS透析保健的业务实力感到不确定,为什么不探索一下我们的交互式股票清单,其中包括一些您可能错过的其他公司的基本经营实质呢?
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Moomoo Securities Australia Limited提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Moomoo Securities Australia Limited, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Moomoo Securities Australia Limited提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Moomoo Securities Australia Limited, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧
